GUIDE
Peptides for Weight Management
Distinguishes approved incretin medications from unapproved weight-loss peptide claims.
What to ask your clinician
Which claims are label-based, which are investigational, and which safety warnings apply to your situation?
Evidence distinction
Human randomized data, observational reports, animal studies, and marketing claims are ranked separately.
Regulatory distinction
Approved medications, supplements, cosmetic ingredients, compounded products, and RUO compounds are not equivalent.
Plain-English guide
Distinguishes approved incretin medications from unapproved weight-loss peptide claims.
Use this guide as a map, not a recommendation list. Start by separating approved product labels from research-only, supplement, cosmetic, and marketing claims. Then compare evidence grade, route, safety score, and source quality before reading individual peptide profiles.
For any peptide with an approved product context, the official label is the primary source for indications, warnings, contraindications, and adverse reactions. For investigational or research-use-only entries, treat the profile as a source-review starting point rather than proof of safety or effectiveness.
Ranked entries
AOD-9604
Metabolic and body-composition research
Cagrilintide
Weight management and metabolic research
Liraglutide
Weight management and type 2 diabetes depending on product label
Semaglutide
Weight management and type 2 diabetes, depending on product label
Tesofensine peptide-adjacent comparison
Weight-management research comparison context
Tirzepatide
Weight management, obstructive sleep apnea in adults with obesity, and type 2 diabetes depending on product label
Ziconotide
Severe chronic pain medication context depending on product label